RET and differentiated thyroid carcinoma: For the initial screening of the effects of these novel formulations, we employed a widely-used in vitro experimental model, represented by two cell lines derived from human papillary thyroid carcinoma, TPC-1, and BCPAP cells, carrying a RET/PTC or BRAFV600E genotypic alteration, respectively [31].